Top

The International Journal of Cardiovascular Imaging

Published in:

01-12-2016 | Original Paper

Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients

Authors: Da-Jun Hu, Jing Xu, Wei Du, Jian-Xin Zhang, Min Zhong, Ya-Nan Zhou

Published in: The International Journal of Cardiovascular Imaging | Issue 12/2016

Abstract

This study was aimed at determining whether late gadolinium enhancement (LGE) in conjunction with Galectin-3 (Gal-3) level offered more precise prognosis of non-ischemic cardiomyopathy (NICM) in comparison to LGE alone. Results of LGE and Gal-3 expression in 192 patients with NICM, including 85 subjects with dilated cardiomyopathy (DCM) and 107 with hypertrophic cardiomyopathy (HCM), were examined. As suggested by the characteristics of LGE and Gal-3 levels, patients were divided into four groups: LGE positive + low Gal-3 (n = 10 for DCM, n = 15 for HCM), LGE positive + high Gal-3 (n = 25 for DCM, n = 51 for HCM), LGE negative + low Gal-3 (n = 32 for DCM, n = 29 for HCM), LGE negative + high Gal-3 (n = 18 for DCM, n = 12 for HCM). Primary endpoints over the follow-up period included major adverse cardiac events (MACEs). Kaplan–Meier survival analysis and univariate Cox proportional hazard models were used to analyze the survival status of patients with NICM. The optimal cut-off value of Gal-3 level for two types of NICM was determined by receiver operating characteristic analysis (13.38 U/L for DCM and 14.40 U/L for HCM). The combination of LGE and Gal-3 levels offered a more significant prognostic value than using LGE alone for both DCM and HCM (DCM P = 0.001 < 0.012; HCM P = 0.037 < 0.040). Moreover, the Cox proportional hazard model suggested that both LGE status [Hazard ratio (HR) = 2.62, P = 0.017] and Gal-3 level (HR = 1.16, P = 0.013) were significant predictors of MACEs in DCM, while they did not appear to have significant prognostic values for HCM (P = 0.06 and 0.64). Furthermore, the multivariate analysis only confirmed LGE as an independent element in predicting prognosis of DCM (HR = 12.19, P = 0.026). In conclusion, LGE status was an independent indicator of DCM prognosis, yet the insignificant role of LGE in HCM prognosis could be limited by sample size.

Smith N, Steeds R, Masani N et al (2015) A systematic approach to echocardiography in hypertrophic cardiomyopathy: a guideline protocol from the british society of echocardiography. Echo Res Pract 2:G1–G7. doi:10.1530/ERP-14-0115 CrossRefPubMedPubMedCentral

Khan R, Massel D, Stirrat J et al (2013) Myocardial fibrosis and quality of life in patients with non-ischemic cardiomyopathy: a cardiovascular magnetic resonance imaging study. Int J Cardiovasc Imaging 29:395–404. doi:10.1007/s10554-012-0107-4 CrossRefPubMed

Maron BJ, Towbin JA, Thiene G et al (2006) Contemporary definitions and classification of the cardiomyopathies: an american heart association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation 113:1807–1816. doi:10.1161/CIRCULATIONAHA.106.174287 CrossRefPubMed

Basso C, Thiene G, Corrado D et al (2000) Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 31:988–998. doi:10.1053/hupa.2000.16659 CrossRefPubMed

Mann DL, Bristow MR (2005) Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111:2837–2849. doi:10.1161/CIRCULATIONAHA.104.500546 CrossRefPubMed

Masci PG, Schuurman R, Andrea B et al (2013) Myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: a contrast-enhanced cardiovascular magnetic study. Circ Cardiovasc Imaging 6:790–799. doi:10.1161/CIRCIMAGING.113.000438 CrossRefPubMed

Olivotto I, Maron BJ, Appelbaum E et al (2010) Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 106:261–267. doi:10.1016/j.amjcard.2010.03.020 CrossRefPubMed

Wu TJ, Ong JJ, Hwang C et al (1998) Characteristics of wave fronts during ventricular fibrillation in human hearts with dilated cardiomyopathy: role of increased fibrosis in the generation of reentry. J Am Coll Cardiol 32:187–196CrossRefPubMed

Pogwizd SM, McKenzie JP, Cain ME (1998) Mechanisms underlying spontaneous and induced ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy. Circulation 98:2404–2414CrossRefPubMed

10.

Perazzolo Marra M, De Lazzari M, Zorzi A et al (2014) Impact of the presence and amount of myocardial fibrosis by cardiac magnetic resonance on arrhythmic outcome and sudden cardiac death in nonischemic dilated cardiomyopathy. Heart Rhythm 11:856–863. doi:10.1016/j.hrthm.2014.01.014 CrossRefPubMed

11.

White JA, Patel MR (2007) The role of cardiovascular mri in heart failure and the cardiomyopathies. Cardiol Clin 25(71–95):vi. doi:10.1016/j.ccl.2007.02.003

12.

Ahn MS, Kim JB, Joung B et al (2013) Prognostic implications of fragmented qrs and its relationship with delayed contrast-enhanced cardiovascular magnetic resonance imaging in patients with non-ischemic dilated cardiomyopathy. Int J Cardiol 167:1417–1422. doi:10.1016/j.ijcard.2012.04.064 CrossRefPubMed

13.

Mewton N, Liu CY, Croisille P et al (2011) Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol 57:891–903. doi:10.1016/j.jacc.2010.11.013 CrossRefPubMed

14.

Bruder O, Wagner A, Jensen CJ et al (2010) Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 56:875–887. doi:10.1016/j.jacc.2010.05.007 CrossRefPubMed

15.

Masci PG, Barison A, Aquaro GD et al (2012) Myocardial delayed enhancement in paucisymptomatic nonischemic dilated cardiomyopathy. Int J Cardiol 157:43–47. doi:10.1016/j.ijcard.2010.11.005 CrossRefPubMed

16.

Lehrke S, Lossnitzer D, Schob M et al (2011) Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart 97:727–732. doi:10.1136/hrt.2010.205542 CrossRefPubMed

17.

Wu KC, Weiss RG, Thiemann DR et al (2008) Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol 51:2414–2421. doi:10.1016/j.jacc.2008.03.018 CrossRefPubMedPubMedCentral

18.

Assomull RG, Prasad SK, Lyne J et al (2006) Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 48:1977–1985. doi:10.1016/j.jacc.2006.07.049 CrossRefPubMed

19.

de Leeuw N, Ruiter DJ, Balk AH et al (2001) Histopathologic findings in explanted heart tissue from patients with end-stage idiopathic dilated cardiomyopathy. Transpl Int 14:299–306CrossRefPubMed

20.

Sharma UC, Pokharel S, van Brakel TJ et al (2004) Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110:3121–3128. doi:10.1161/01.CIR.0000147181.65298.4D CrossRefPubMed

21.

Weir RA, Petrie CJ, Murphy CA et al (2013) Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail 6:492–498. doi:10.1161/CIRCHEARTFAILURE.112.000146 CrossRefPubMed

22.

Dumic J, Dabelic S, Flogel M (2006) Galectin-3: an open-ended story. Biochim Biophys Acta 1760:616–635. doi:10.1016/j.bbagen.2005.12.020 CrossRefPubMed

23.

Yang RY, Rabinovich GA, Liu FT (2008) Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 10:e17. doi:10.1017/S1462399408000719 CrossRefPubMed

24.

Reifenberg K, Lehr HA, Torzewski M et al (2007) Interferon-gamma induces chronic active myocarditis and cardiomyopathy in transgenic mice. Am J Pathol 171:463–472. doi:10.2353/ajpath.2007.060906 CrossRefPubMedPubMedCentral

25.

Thandavarayan RA, Watanabe K, Ma M et al (2008) 14-3-3 protein regulates ask1 signaling and protects against diabetic cardiomyopathy. Biochem Pharmacol 75:1797–1806. doi:10.1016/j.bcp.2008.02.003 CrossRefPubMed

26.

de Boer RA, Lok DJ, Jaarsma T et al (2011) Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43:60–68. doi:10.3109/07853890.2010.538080 CrossRefPubMed

27.

Lok DJ, Van Der Meer P, de la Porte PW et al (2010) Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 99:323–328. doi:10.1007/s00392-010-0125-y CrossRefPubMedPubMedCentral

28.

Lok DJ, Lok SI, Bruggink-Andre de la Porte PW et al (2013) Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clinical Res Cardiol 102:103–110. doi:10.1007/s00392-012-0500-y CrossRef

29.

Elliott PM, Anastasakis A, Borger MA et al (2014) [2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy]. Kardiol Pol 72:1054–1126. doi:10.5603/KP.2014.0212 CrossRefPubMed

30.

Kim RJ, Shah DJ, Judd RM (2003) How we perform delayed enhancement imaging. J Cardiovasc Magn Reson 5:505–514CrossRefPubMed

31.

Gao P, Yee R, Gula L et al (2012) Prediction of arrhythmic events in ischemic and dilated cardiomyopathy patients referred for implantable cardiac defibrillator: evaluation of multiple scar quantification measures for late gadolinium enhancement magnetic resonance imaging. Circ Cardiovasc Imaging 5:448–456. doi:10.1161/CIRCIMAGING.111.971549 CrossRefPubMed

32.

Morgan RB, Kwong R (2015) Role of cardiac MRI in the assessment of cardiomyopathy. Curr Treat Options Cardiovasc Med 17:53. doi:10.1007/s11936-015-0410-1 CrossRefPubMed

33.

Johnston DL, Rokey R, Okada RD (1987) Nuclear magnetic resonance imaging of the cardiovascular system. Herz 12:51–67PubMed

34.

Masci PG, Schuurman R, Barison A et al (2013) Response to letters regarding article, “myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: a contrast-enhanced cardiovascular magnetic study”. Circ Cardiovasc Imaging 6:e79. doi:10.1161/CIRCIMAGING.113.001217 CrossRefPubMed

35.

Li X, Cai C, Luo R et al (2015) The usefulness of age and sex to predict all-cause mortality in patients with dilated cardiomyopathy: a single-center cohort study. Clin Interv Aging 10:1479–1486. doi:10.2147/CIA.S88565 CrossRefPubMedPubMedCentral

36.

Cheng L, Zhao R, Jin Z et al (2015) Association of genetic polymorphisms on btnl2 with susceptibility to and prognosis of dilated cardiomyopathy in a chinese population. Int J Clin Exp Pathol 8:10488–10499PubMedPubMedCentral

37.

Ismail TF, Prasad SK, Pennell DJ (2012) Prognostic importance of late gadolinium enhancement cardiovascular magnetic resonance in cardiomyopathy. Heart 98:438–442. doi:10.1136/heartjnl-2011-300814 CrossRefPubMed

38.

Rodriguez-Capitan J, Garcia-Pinilla JM, Ruiz-Zamora I et al (2015) Reply to the letter “prognostic value of late gadolinium enhancement in cardiomyopathy: causative risk factor or surrogate marker?” Int J Cardiol 181:102–103. doi:10.1016/j.ijcard.2014.12.007 CrossRefPubMed

39.

Rodriguez-Capitan J, Garcia-Pinilla JM, Ruiz-Zamora I et al (2014) Long-term prognostic value of late gadolinium enhancement in a cohort of patients with nonischemic dilated cardiomyopathy. Int J Cardiol 177:17–19. doi:10.1016/j.ijcard.2014.09.110 CrossRefPubMed

40.

Vergaro G, Del Franco A, Giannoni A et al (2015) Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy. Int J Cardiol 184:96–100. doi:10.1016/j.ijcard.2015.02.008 CrossRefPubMed

41.

Ise T, Hasegawa T, Morita Y et al (2014) Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis. Heart 100:1165–1172. doi:10.1136/heartjnl-2013-305187 CrossRefPubMed

42.

Gucuk Ipek E, Akin Suljevic S, Kafes H et al (2015) Evaluation of galectin-3 levels in acute coronary syndrome. Ann Cardiol Angeiol doi:10.1016/j.ancard.2015.09.046

43.

Yakar Tuluce S, Tuluce K, Cil Z et al (2015) Galectin-3 levels in patients with hypertrophic cardiomyopathy and its relationship with left ventricular mass index and function. Anatol J Cardiol. doi:10.5152/AnatolJCardiol.2015.6191

44.

Cuspidi C, Tadic M, Sala C (2015) Galectin-3 and hypertensive heart disease. J Clin Hypertens (Greenwich). doi:10.1111/jch.12756

45.

French B, Wang L, Ky B et al (2015) Prognostic value of galectin-3 for adverse outcomes in chronic heart failure. J Card Fail. doi:10.1016/j.cardfail.2015.10.022

46.

Guglin M, Verma S (2012) Right side of heart failure. Heart Fail Rev 17:511–527. doi:10.1007/s10741-011-9272-0 CrossRefPubMed

47.

Freed BH, Gomberg-Maitland M, Chandra S et al (2012) Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. J Cardiovasc Magn Reson 14:11. doi:10.1186/1532-429X-14-11 CrossRefPubMedPubMedCentral

Title: Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients
Authors: Da-Jun Hu
Jing Xu
Wei Du
Jian-Xin Zhang
Min Zhong
Ya-Nan Zhou
Publication date: 01-12-2016
Publisher: Springer Netherlands
Published in: The International Journal of Cardiovascular Imaging / Issue 12/2016
Print ISSN: 1569-5794
Electronic ISSN: 1875-8312
DOI: https://doi.org/10.1007/s10554-016-0958-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2016

Two-dimensional and three-dimensional left ventricular deformation analysis: a study in competitive athletes

Multilayer longitudinal strain at rest may help to predict significant stenosis of the left anterior descending coronary artery in patients with suspected non-ST-elevation acute coronary syndrome

In-vivo validation of a new clinical tool to quantify three-dimensional myocardial strain using ultrasound

Optimisation of coronary vascular territorial 3D echocardiographic strain imaging using computed tomography: a feasibility study using image fusion

Improved border sharpness of post-infarct scar by a novel self-navigated free-breathing high-resolution 3D whole-heart inversion recovery magnetic resonance approach

Regression equations of Z score and echocardiographic nomograms for coronary sinus in healthy children